Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amplia Therapeutics ( (AU:ATX) ) has provided an update.
Amplia Therapeutics Limited has announced a change in its registered office and principal place of business to Level 5, 90 William Street, Melbourne VIC 3000. This move is a strategic decision for the company, which is actively advancing its pipeline of FAK inhibitors. The change in location could potentially enhance operational efficiency and align with the company’s focus on developing treatments for fibrotic cancers and chronic diseases, thereby impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for treating cancer and fibrosis. The company has a particular interest in fibrotic cancers such as pancreatic and ovarian cancer, and FAK’s role in chronic diseases like idiopathic pulmonary fibrosis (IPF).
Average Trading Volume: 7,041,018
Technical Sentiment Signal: Buy
Current Market Cap: A$114.3M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.